caa a22 4500 465789722 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171989 doi (NATIONALLICENCE)springer-10.1007/BF00171989 Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer [Elektronische Daten] [Michael Simon, John Eckenrode, Ronald Natale] Summary: Methylglyoxal bis-guanylhydrazone (MGBG), a potent inhibitor of polyamine synthesis, has demonstrated single agent activity against a number of tumor types including malignant lymphomas and head and neck, esophageal and non-small cell lung cancers. The growth of small cell lung cancer (SCLC) cell lines can be arrested by polyamine inhibition. Therefore a phase II trial was conducted in twenty-four patients with refractory SCLC. MGBG was administered by intravenous infusion at a dose of 500 mg/m2 per week for four cycles and then every two weeks thereafter. The dose was escalated by 100 mg/m2 every two weeks in the absence of toxicity ⩾ grade 2. One patient achieved a partial response of objectively measurable lung disease and supraclavicular adenopathy. Three patients had stable disease. Dose limiting toxicity consisted primarily of mild to moderate nausea, vomiting, stomatitis and/or diarrhea. Myelosuppression was uncommon and rarely dose limiting. We conclude that MGBG in the dose and schedule used does not have significant activity as a single agent in previously treated small cell lung cancer. Kluwer Academic Publishers, 1990 MGBG nationallicence polyamine inhibitor nationallicence phase II study nationallicence small cell lung cancer nationallicence Simon Michael Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA aut Eckenrode John Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA aut Natale Ronald Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S79-S81 0167-6997 8<S79 1990 8 10637 https://doi.org/10.1007/BF00171989 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171989 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Simon Michael Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA aut NATIONALLICENCE 700 1- Eckenrode John Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA aut NATIONALLICENCE 700 1- Natale Ronald Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S79-S81 0167-6997 8<S79 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer